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Abstract
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer
(LABC) that effects approximately 5% of women with breast cancer annually in the USA. It is
a clinically and pathologically distinct form of LABC that is particularly fast growing, invasive,
and angiogenic. Nearly all women have lymph node involvement at the time of diagnosis, and
approximately 36% have gross distant metastases. Despite recent advances in multimodality
treatments, the prognosis of patients with IBC is poor, with a median disease-free survival of
less than 2.5 years. Recent work on the genetic determinants that underlie the IBC
phenotype has led to the identification of genes that are involved in the development and
progression of this disease. This work has been aided by the establishment of primary
human cell lines and animal models. These advances suggest novel targets for future
interventions in the diagnosis and treatment of IBC.
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labeling index; PgR = progesterone receptor; VEGF = vascular endothelial growth factor.
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Introduction
IBC is a form of LABC that was first described by Lee and
Tannenbaum in 1924 [1]. The unique clinical and patho-
logic syndrome and discouraging outcome make IBC a
very distinct form of breast carcinoma. Three biologic fea-
tures make IBC unique. First, it is rapidly progressive,
being the most lethal type of LABC. Second, it is highly
angiogenic and angioinvasive. Third, its aggressive behav-
ior and angiogenicity are intrinsic characteristics of the
tumor, and are present from its inception. The angiogenic-
ity and propensity to invade vessels confer to IBC an
extremely high metastatic potential.
The designation ‘inflammatory’ stems from the clinical
appearance, which mimics an acute inflammation of the
breast. IBC is a clinical diagnosis. Haagensen [2] required
at least one-third of the breast to be involved with ‘grave
signs’ of breast cancer to make a diagnosis, but others
have shown that patients with less than one-third involve-
ment of the breast have a similarly poor prognosis [3].
Pathologists rely on the finding of dermal lymphatic
involvement to confirm the clinical diagnosis, and a skin
biopsy should be performed when there is clinical suspi-
cion of IBC. Although in many patients the clinical andBreast Cancer Research    Vol 2 No 6 Kleer et al
pathologic findings coincide, this is not always the case.
There are patients with the typical clinical syndrome in
whom skin biopsy fails to demonstrate lymphatic tumor
emboli. In some instances, the skin changes may repre-
sent acute mastitis, diffuse leukemic or lymphomatous infil-
trate, or advanced noninflammatory breast cancer. On the
other hand, lymphatic tumor emboli in the dermis are not
always found in patients with IBC, mainly due to sampling
heterogeneity. Importantly, tumor emboli in the dermal lym-
phatics can be observed incidentally in breast cancer,
without any clinical evidence of IBC; such cases are not
considered to be IBC, despite the pathologic findings.
The term ‘primary IBC’ refers to a de novo IBC. All
patients with primary IBC have an underlying invasive
mammary carcinoma, which may or may not be evident
clinically or on mammogram at the time of diagnosis. ‘Sec-
ondary IBC’ is the inflammatory recurrence of a noninflam-
matory primary breast carcinoma. Secondary IBC usually
occurs on the chest wall at the site of previous mastec-
tomy for a noninflammatory breast cancer, but occasion-
ally may be found at a distant cutaneous recurrence. The
term ‘occult IBC’ describes a group of patients who have
cutaneous and parenchymal lymphatic tumor emboli that
are associated with their primary tumor in the absence of
skin erythema. Because the diagnosis of IBC should be
made on the basis of clinical features, the term ‘occult
IBC’ is confusing and should be abandoned.
Clinical and pathologic features of invasive
breast cancer
IBC represents 1–6% of all breast cancers [4]. The age
distribution is not significantly different from that of ordi-
nary infiltrating carcinoma, averaging around 55 years,
with most patients being postmenopausal [4].
The typical patient presents with pain and a tender, firm,
and enlarged breast. The skin over the breast is reddened,
warm, and thickened, and is termed ‘peau d’orange’ (skin
of an orange). In the earliest phase a mass may not be pal-
pable. These signs and symptoms are characteristically
rapidly progressive, with a median duration before diagno-
sis of less than 2 months.
Pathologically, IBC is highly angiogenic and angioinvasive.
Although it is not a specific histologic subtype of
mammary carcinoma, the presence of numerous ectatic
and dilated dermal lymphatics clogged by malignant cells
constitutes the histologic hallmark that may accompany
the symptoms. Malignant cells invade the dermal lym-
phatic vessels and form tumor emboli, which are responsi-
ble for the clinical signs and symptoms, and ultimately for
the development of metastases [5].
Primary IBC is often of ductal type, with prominent angio-
lymphatic invasion. It has a high histologic grade, with
pleomorphic tumor cells and highly atypical mitotic figures.
In contrast to secondary IBC, in primary IBC invasion of
the dermis outside the lymphatic vessels is uncommon.
Interestingly, the skin within and outside the zone of ery-
thema appear histologically identical, with tumor emboli
frequently present in areas that are clinically unremarkable
[5]. It has been suggested [6] that primary breast carcino-
mas with prominent apocrine features are associated with
increased incidence of inflammatory recurrences.
Prognosis and treatment
IBC is a major challenge to oncologists who treat breast
cancer. Until the introduction of combined modality treat-
ment, less than 5% of patients survived 5 years [6]. IBC
presents two therapeutic challenges. The first one is to
target its high metastatic potential and prevent distant
metastatic failures, which may be present even before
detection of the primary tumor. To achieve this goal pro-
longed neoadjuvant systemic therapy is advocated. The
second challenge is to achieve local/regional disease
control by using radiation, surgery, and chemotherapy. For
these reasons, a multimodality treatment approach is cur-
rently used to treat patients with IBC.
Haagensen and Stout [7] emphasized the poor outlook for
this group of breast cancer patients, as they were consid-
ered inoperable. Improved radiation techniques have
increased the chances of achieving local control [8]. Radio-
therapy alone yielded 5-year survivals of 12–38% in different
series [9]. Combination of surgery and radiotherapy has
resulted in 5-year survivals of 35–55% in some studies [10].
The hypothesis that virtually all patients with IBC have dis-
seminated micrometastatic disease at presentation and the
discouraging patient outcome urged the use of chemother-
apy as the first-line of treatment (neoadjuvant), and after
surgery and/or radiation as a pivotal tool in the treatment of
patients with IBC. In a retrospective study from the
Harvard-Joint Center for Radiation Therapy, USA [9], 41
patients with stage III breast cancer, who received post-
irradiation adjuvant therapy with either chemotherapy alone
or combined with an endocrine-ablative procedure, had a
significantly better disease-free survival at 4 years (51%).
The Milan group [11] was the first to introduce the use of
combination chemotherapy before local therapy. In 110
patients, they achieved an overall disease-free survival of
53% at 3 years, compared with an overall disease-free sur-
vival of 41% for a control group that was treated with radia-
tion therapy alone. A similar treatment strategy was used
by Hortobagyi et al [12] at the MD Anderson Hospital.
The largest series of patients with IBC was reported by
Rouesse et al [13], who studied 230 patients who were
subjected either to radiation treatment alone (group C); to
three cycles of neoadjuvant chemotherapy, one cycle during
radiation and one cycle after radiation (group A); or to threehttp://breast-cancer-research.com/content/2/6/423
cycles of neoadjuvant chemotherapy, one cycle during radi-
ation, followed by five cycles of chemotherapy (group B). All
patients had hormonal treatment as well. There were signifi-
cant differences in the 4-year disease-free survival and
overall survival rates, which were 16 and 28% for patients in
group C, 28 and 44% for patients in group A, and 46 and
66% for patients in group B, respectively. Taken together,
these studies led to the conclusion that neoadjuvant
chemotherapy resulted in considerable tumor regression
that enhanced the ability either to perform a surgical resec-
tion or to deliver a tumoricidal dose of radiation.
The concept of prolonged neoadjuvant chemotherapy
treatment to the point of maximal objective clinical
response emerged in the mid-1970s. Swain et al [14]
treated 76 patients with stage IIIA, IIIB, and IV breast
cancers. All patients received a variable number of neoad-
juvant chemotherapy cycles until the maximum objective
clinical response was attained. This group obtained com-
plete remission in 49% and partial remission in 44% of
patients. The median numbers of cycles of chemotherapy
in this study were three for partial responders and five for
complete responders.
At the University of Michigan, we studied a group of stage
III breast cancer patients (n = 89), which included 36
(40%) patients with IBC [15]. These patients were treated
with neoadjuvant chemohormonal treatment followed by
local/regional therapy with radiotherapy alone or surgery
plus radiotherapy, and finally with consolidation chemohor-
monal treatment. Clinical complete remission was
achieved in 53% and clinical partial remission in 41% of
IBC patients. Pathologic complete and partial responses
were seen in 25 and 75% of patients, respectively. An
encouraging 94% response rate (clinical complete
response plus clinical partial response) to chemotherapy
was achieved, with an overall survival rate of 54% at
5 years. Despite these initial responses, however, the esti-
mated 5-year disease-free survival and overall survival
rates were 35 and 37%, respectively. The total response
rate for patients with IBC in our study was comparable to
rates observed by other groups [16,17].
In summary, the multidisciplinary approach to the treat-
ment of IBC with neoadjuvant chemotherapy to maximal
clinical response, followed by local/regional treatment and
consolidation chemotherapy, has improved survival and
disease-free survival, and constitutes the mainstream of
current treatment for patients with IBC. Below, we discuss
work that has been undertaken to improve our understand-
ing of the molecular basis of the IBC phenotype.
Molecular genetics of inflammatory breast
cancer
Although the histomorphologic features of IBC have been
well described in numerous publications (for review [18]),
the molecular basis of the disease has only been investi-
gated in a handful of studies. The vast majority of these
investigations focused on the hormone receptor status and,
to a lesser extent, on the p53 tumor suppressor status of
patient samples, seeking to establish a correlation between
expression of these genes and the poor clinical outcome.
Hormone receptor status
In general, the absence of estrogen receptor (ER) and
progesterone receptor (PgR) expression has been corre-
lated with a shorter disease-free survival time and overall
poor clinical outcome of breast cancer patients, including
those with IBC [19]. Studies from 1981 to 1990 have
described the ER and PgR status of patient IBC samples
and their relationship to prognosis [20]. Using the dextran-
coated charcoal technique to determine the levels of the
cytosolic receptors [21], this work revealed that IBC
tumors were predominately ER- and PgR-negative, with
26–100% of the samples being negative for both recep-
tors. Furthermore, the levels of expression of these recep-
tors alone had no prognostic significance for IBC.
In a study of a heterogeneous collection of 60 LABC
tumor specimens [22], seven biologic features of the
tumors were analyzed with respect to prognosis. It was
found that response to treatment, and therefore a more
favorable prognosis, was significantly correlated with ER
and PgR positivity, a lower mitotic index, histologic grade,
and diploid tumors in patients with LABC.
In an attempt to identify unique biologic characteristics
that could be used as prognostic markers, Paradiso et al
[23] compared the hormone receptor status and cell kinet-
ics of IBC versus other LABC tumors. That study exam-
ined ER, PgR, and 3H-thymidine labeling index (LI) of 28
IBC and 50 non-IBC tumors. Compared with non-IBC
LABC, IBC tumors frequently lacked expression of the
cytosolic ER (44% of IBC tumors were ER positive versus
64% of LABC) and PgR (30% of IBC tumors were PgR
positive versus 51% of LABC), regardless of menopausal
status. However, that study demonstrated that IBC cell
kinetics were typically twofold higher than non-IBC
tumors, and that the mean LI of IBC tumors was 1.5-fold
greater in premenopausal women than in postmenopausal
women. An apparent relationship between hormonal
receptor status and LI was also noted. IBC tumors that
were ER negative tended to have twice the LI of the ER-
positive IBC tumors. Although the time to progression was
similar for IBC tumors with either low or high LI, those
patients whose tumors had a lower LI and were PgR posi-
tive survived longer (31 months) than did those whose
tumors were PgR negative with a high LI (18 months).
These results suggest that ER- and PgR-negative status
and high LI cell kinetics may be useful markers for identifi-
cation of patients who have a poorer clinical outcome
manifested as decreased overall survival.Breast Cancer Research    Vol 2 No 6 Kleer et al
In order to investigate the relationship between ER expres-
sion and the expression of the proto-oncogene c-myb in
breast cancer, an analysis of 112 non-IBC specimens and
57 IBC specimens was conducted [24]. Expression of the
ER and PgR genes, c-myb, c-erb2, c-myc, c-fos, the epi-
dermal growth factor receptor (EGFR) gene, and pS2 (a
small secreted protein isolated from MCF7 cells after
induction by 17b-estradiol) were analyzed in that study.
The IBC specimens were found to be predominately posi-
tive for the EGFR gene (58%) and c-erb2 (60%). Expres-
sion of c-myb was found to correlate inversely with c-erb2
expression, and was higher in non-IBC samples (63%
versus 38%). Expression of the other genes was approxi-
mately the same for non-IBC and IBC specimens, and no
statistically significant differences were found. 
Taken together, all of these studies have established that
the majority of IBC tumors are ER and PgR negative,
EGFR and c-erb2 positive, and have a rapid growth rate.
Although nonspecific for IBC, these molecular markers
may serve as general prognostic markers.
The p53 tumor suppressor gene in inflammatory breast
cancer
Mutations in the p53 tumor suppressor gene are the most
common mutations found in human cancers [25,26]. Wild-
type p53 can act as a negative regulator of cell prolifera-
tion through induction of cell cycle arrest or through the
induction of the cell’s apoptotic machinery [27]. Mutations
at the p53 locus constitute the most common mechanism
to abrogate the regulatory effects of p53.
This is certainly the case with colorectal carcinoma, in
which over 70% of cases have a mutation in p53 [28].
Studies have indicated that on average 30% of breast
cancers contain mutations in one of the p53 alleles [29].
Furthermore, it has been demonstrated that, on progres-
sion, approximately 60% of these breast cancers lose the
mutant allele and retain the wild-type allele [30]. A study by
Moll et al [31] described two mechanisms that alter p53
function in a panel of 27 IBC cases. Using immunohisto-
chemistry, they found that the cases fell almost equally into
three distinct groups: tumors with high levels of p53
detected in the nucleus, tumors with no detectable p53
staining, and tumors that stained for p53 in the cytoplasm.
Direct sequencing demonstrated only wild-type p53 in the
samples with cytoplasmic p53 staining or no detectable
p53 staining. The samples that contained intense nuclear
staining for p53 contained a variety of missense mutations
that were clustered in exons 5–8. These results suggest
that two distinct mechanisms, direct mutation or cytoplas-
mic sequestration of the wild-type protein, can subvert the
normal role of p53 in IBC and in other breast cancers.
In an attempt to correlate p53 status with prognosis, the
analysis was extended by an additional group of 24 IBC
patients, who were screened for p53 mutations, p53
mRNA levels, and protein expression [32]. Using multivari-
ate analysis, a positive correlation with p53 nuclear
expression and poor clinical outcome was observed.
Those patients with a p53 gene mutation and nuclear
over-expression of the p53 protein had an 8.6-fold higher
risk of death compared with patients who had neither
mutation nor protein over-expression. Furthermore, when
combined with ER data, it was found that the subset of
patients who were ER negative and had nuclear over-
expression of p53 had a 17.9-fold higher risk of death,
compared with 2.8-fold for those women who had p53
nuclear over-expression alone. Together, the data from this
group implicate p53 expression status as a strong indica-
tor of overall survival, alone and in combination with other
known prognostic markers.
These conclusions were confirmed in a study of 39
LABCs with inflammatory signs [33], 32 of which were
confirmed as IBCs by clinical and pathologic criteria.
Using a combination of immunohistochemistry, poly-
merase chain reaction, single-strand conformational poly-
morphism, and direct sequencing, p53 mutations were
detected in 41% of the tumors analyzed. Again, the major-
ity of mutations were localized to exons 5–8, the muta-
tional hot-spot for p53 found in most cancers. In addition,
all but three of the tumors had intense p53 nuclear stain-
ing. The presence of p53 mutations was significantly asso-
ciated with large tumor size and the presence of overt
metastasis at the time of diagnosis. A weak association
between p53 mutation, negative ER status, and lower
response rate to therapy was also apparent.
These data give a prognostic value to determining the ER
and p53 status of individual patients in order to determine
who may fail or have only a minor response to neoadjuvant
therapy. The above work showed that known markers of
poor outcome in general also contributed to poor outcome
in IBC. However, this work did not suggest how the spe-
cific features of the IBC phenotype might result from these
genetic alterations.
Genetic determinants of the inflammatory breast cancer
phenotype
In an effort to identify new genes that may determine the
rapidly growing and metastatic features of the IBC pheno-
type, our laboratory began a study of genes that are differ-
entially expressed in an IBC cell line (SUM149) as
compared with human mammary epithelial (HME) cells
[34]. Seventeen transcripts were identified as being differ-
entially expressed between the SUM149 IBC cell line and
two HME cell lines of the same mammary differentiation
lineage. Eight of the transcripts were found to be
expressed solely by the normal cell lines and not by the
tumor. The remaining nine transcripts were expressed
exclusively by the tumor cell line. In an analysis that wasblind to the IBC or non-IBC status of the samples, 20
archival IBC and 30 stage-matched non-IBC specimens
were tested by in situ hybridization for expression of the
17 differentially expressed transcripts. In an example of
basic research stemming from a clinical study, the
samples used in the in situ hybridization experiments were
collected over the course of almost 10 years in a prospec-
tive, nonrandomized clinical trial at the University of Michi-
gan [15]. Two genes, RhoC GTPase and a novel gene,
were found to be concordantly altered in 91% of the IBC
specimens versus 0% of the stage-matched non-IBC
tumors. The putative oncogene, RhoC GTPase, was
found to be over-expressed in 90% of the IBC tumors ana-
lyzed, compared with 38% of the non-IBC specimens.
Expression of the novel gene, called LIBC (lost in inflam-
matory breast cancer), was found to be lost in 80% of IBC
specimens versus in only 21% of noninflammatory tumors.
The protein encoded by LIBC has subsequently been
identified as an insulin-like growth factor (IGF)-binding
protein related protein (IGFBP-rP), and officially re-named
IGFBP-rP9 [35].
The  Rho (Ras homology) gene was first isolated from
Aplysia, and has been shown to be highly conserved
throughout evolution [36]. Transfection of Aplysia Rho
(which is 92% homologous to human RhoC) into NIH3T3
cells led to malignant transformation of the cells [37].
RhoC GTPase is involved in cytoskeletal reorganization;
specifically, it is involved in the formation of actin stress
fibers and focal adhesion contacts [38]. In addition to
increased stress fiber and focal adhesion contact forma-
tion, over-expression of RhoC could activate other Rho
family members (ie RhoA, rac and/or cdc42) through sig-
naling feedback loops [39], leading to dynamic cytoskele-
tal reorganization and a motile/metastatic cell.
Preliminary data from our laboratory indicate that this is
probably the case. Transfection and over-expression of
RhoC GTPase in Epstein–Barr virus-immortalized HME
cells produce highly motile and invasive tumorigenic
clones (van Golen et al, unpublished data). These data,
combined with the observation that over-expression of
RhoC GTPase correlates with tumor progression in
aggressive ductal adenocarcinoma of the pancreas [40],
suggest that RhoC is a key element in the IBC metastatic
phenotype.
At this time, the role of the protein encoded by LIBC
(IGFBP-rP9) in IBC is less clear. The functions of
IGFBP-rPs are at this time unknown. It is speculated the
high-affinity IGF-binding proteins and the IGFBP-rPs modu-
late the availability of IGF to the cell, and therefore regulate
the availability of IGF to the IGF receptors [41]. This, in turn
regulates and potentiates IGF-mediated proliferative and
anabolic effects on the cell. In addition, these proteins may
also exert IGF-independent effects on a cell [42].
There is evidence in the literature for the role of IGFBP-rPs
in tumor progression. Downregulation or loss of IGFBP-rP1
expression is associated with progression of breast
cancer [43] and prostate cancer [44]. Transfection of
IGFBP-rP1 in prostate cancer cells gives rise to a less
malignant phenotype, in a manner that is directly propor-
tional to the level of expression [44]. Together, RhoC
GTPase and LIBC provide promising new avenues of
study that could lead to new prognostic tools and thera-
peutic targets for IBC.
Cytokines in inflammatory breast cancer
As already mentioned, the term ‘IBC’ is somewhat of a
misnomer. The ‘inflammation’ of the breast, which
prompted Lee and Tannenbaum [1] to coin the phrase
‘inflammatory breast cancer’, is actually caused by block-
age of the dermal lymphatics by tumor infiltrate, and not by
infiltration of inflammatory cells. IBC tumors produce negli-
gible levels of most inflammatory cytokines, including
IFN-g, IL-1, and IL-12 (van Golen and Merajver, unpub-
lished data); consequently, host inflammatory cells are
rarely detected around the tumor stroma [5].
In addition to being lymphotactic, IBCs tend to be highly
vascular tumors due to their angiogenic and angioinvasive
potential [5]. Analysis of IBC tumor cell lines and archival
tumor specimens demonstrated that high levels of vascu-
lar endothelial growth factor (VEGF), basic fibroblast
growth factor, IL-6, and IL-8 are expressed and secreted
by the tumor cells (unpublished data).
The VEGF receptor-3 is found on the epithelium of lym-
phatic vessels and is known to bind the recently identified
VEGF family members VEGF-C and VEGF-D [45]. A
variety of breast cancer cell lines were screened for
expression levels of the VEGF family members (VEGF-A,
-B, -C, and -D) [46]. VEGF-A and -B, which are important
in regulating tumor angiogenesis, were found to be
expressed by all of the breast cancers analyzed, regard-
less of type. However, VEGF-D was detected only in an
IBC cell line and in a tumor cell line that was developed
from an inflammatory skin metastasis.
These data suggest that the expression of VEGF-A and -B
might be responsible for neovascularization of the tumor,
whereas VEGF-D may be specifically involved in the lym-
photactic process through the development of new lym-
phatic vessels near the tumor. The work of understanding
the specific mediators of IBC is at its inception. The
models described below will be helpful in this pursuit.
In vitro and in vivo models to study
inflammatory breast cancer
Recently new models have been developed to study IBC.
Cell lines, such as the SUM149 and SUM190, which are
derived from primary IBC tumors, will be valuable for in
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vitro studies of the IBC phenotype [47]. These cell lines
have been well characterized with respect to expression of
hormonal receptors, p53 status, and cytogenetic abnor-
malities. In addition, several less well-characterized cell
lines derived from confirmed IBCs are available from the
American Type Culture Collection. Both the SUM149 and
SUM190 cell lines are known to form tumors in nude mice
after mammary fat pad injection with large uptake rates
(80–100%).
A unique xenograft model, MARY-X, has been established
[48]. Implantation of a human IBC tumor into the mammary
fat pad of an immunocompromised mouse has established
a tumor that accurately reflects some clinical symptoms of
IBC in a mouse model. The establishment of these in vivo
models will facilitate the characterization of IBC pheno-
type–genotype relationships.
Conclusion
The challenges before us are, on one hand, to discover
novel treatment modalities that target essential steps that
are involved in the development of IBC, such as those
directed against its angiogenic and angioinvasive poten-
tial. On the other hand, new molecular predictors of
tumor response to treatment need to be identified.
Achieving these challenges is likely to result in improved
patient survival.
Initial molecular studies of IBC concentrated on those
genes and gene products that were identified as having
prognostic value in noninflammatory breast cancers.
These studies provided a basis for understanding the role
of these genes in IBC. Moreover, these studies con-
tributed two important conclusions. First, although some
genetic changes in IBC are shared with other forms of
breast cancer, for the most part it is as distinct in its mole-
cular profile as it is in its phenotype. Second, this collec-
tion of studies comparing IBC with other forms of LABC
have led the way in recognizing IBC as a disease that is
distinct from other LABCs. To further characterize the
genotype–phenotype relationship of IBC, breast cancer
researchers will need to recognize that IBC is a distinct
form of LABC. Recent interest in the IBC phenotype has
led to the development of new IBC cell lines such as
SUM149 and SUM190 [47,49], and to a unique xenograft
model, MARY-X [48]. These models will help in investigat-
ing the molecular differences, not only between the cancer
and normal tissue, but also between inflammatory and
noninflammatory disease.
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